Psyence Biomedical (PBM) Equity Average (2024 - 2025)

Psyence Biomedical (PBM) recorded quarterly Equity Average of $2.7 million in Q1 2025, up 144.71% quarter-over-quarter from -$6.1 million in Q3 2024.

Psyence Biomedical (PBM) Equity Average (2024 - 2025) Analysis & Trends

Psyence Biomedical's Equity Average history runs 2 years deep, the most recent figure standing at $2.7 million for Q1 2025.

  • In Q1 2025, Equity Average changed N/A year-over-year to $2.7 million; the TTM figure through Mar 2025 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was -$2.1 million, changed N/A from the prior year.
  • Equity Average was $2.7 million for Q1 2025 at Psyence Biomedical, up from -$6.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $2.7 million in Q1 2025 to a low of -$6.1 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Avg. (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 3.50 Bn
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 783.14 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 3.76 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 1.01 Bn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 21.35 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 19.01 Bn
9 Abivax 91.96 Bn 91.96 Bn - 516.41 Mn
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn 31.34 Bn

Historic Data

Download Data
DateValue
Mar 31, 2025 2.73 Mn
Sep 30, 2024 -6.11 Mn